Original Research Article
Year: 2020 | Month: April | Volume: 7 | Issue: 4 | Pages: 342-345
Sokal & EUTOS Prognostic Scores Are Not Predictive For Clinical Outcome in Patients with Chronic Phase Chronic Myeloid Leukemia Treated With Imatinib
Namrata Bhutani1, Deepika Arora2, Neha Bhutani3
1Department of Biochemistry, Vardhaman Mahavir Medical College & Safdarjung Hospital, New Delhi.
2Department of Anaesthesia, Royal London Hospital, NHS Barts Health, London, United Kingdom
3ESIC Dental College, Rohini, New Delhi
Corresponding Author: Neha Bhutani
ABSTRACT
Introduction: Chronic myeloid leukemia (CML) is a malignant myeloproliferative clonal disorder of hematopoietic stem cells. The response to Imatinib can be assessed by criteria given by European Leukemia Net (ELN 2013 ). CML prognostic scoring systems stratify patients into risk groups based on patient and disease related characteristics at diagnosis. (Sokal,EUTOS).
Methodology: Pre-treatment prognostic scores (Sokal score, EUTOS score) were calculated on the basis of spleen size, platelet count& DLC. After initiation of imatinib therapy, hematological response was monitored at regular intervals &molecular response (BCR-ABL1/ABL1 ratio) assessed after 6 or 12 months.
Results : Cases were divided into two groups, high risk (n=27) & low risk (n=3), based on EUTOS score. 24(88.88%) patients with low risk achieved CHR by the end of 3 months, whereas 2(66.66%) with high risk had it(p=0.3596). An optimal molecular response was seen in 50% of both low risk (n=1) & high risk (n=7) patients based on Sokal score.
Conclusions: In this study, both Sokal and EUTOS score were not predictive for haematological and molecular response in CML patients in chronic phase treated with Imatinib and seem to be inadequate. Better prognostic models need to be suggested for TKI therapy.
Keywords: CML, imatinib, prognostic scores
[PDF Full Text]